Provided by Tiger Trade Technology Pte. Ltd.

AKESO

94.200
+5.3005.96%
Volume:14.51M
Turnover:1.38B
Market Cap:86.76B
PE:-65.52
High:96.900
Open:92.800
Low:92.750
Close:88.900
52wk High:179.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.06
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.438
ROE:-14.53%
ROA:-4.32%
PB:8.22
PE(LYR):-65.52
PS:24.34

Loading ...

Earning Preview: AKESO revenue is expected to increase, institutional views lean positive

Earnings Agent
·
Aug 20

Morning Market Wrap: Hong Kong Shares Rise 0.68% as Copper Stocks Take the Lead

Stock News
·
Yesterday

China's Akeso Jumps on Progress of Immunotherapy Drug for Cancer Treatment

Reuters
·
Yesterday

AKESO Surges Over 9% in Session as Evonex Achieves Positive Phase III Results in Biliary Tract Cancer

Deep News
·
Yesterday

Akeso's Ivonescimab Meets Primary Endpoint in Phase 3 Biliary Tract Cancer Trial

MT Newswires Live
·
Yesterday

Movement Alert|AKESO Rises 6.64% in Regular Trading, Phase III Trial for Ivonescimab in Biliary Tract Cancer Achieves Significant OS Benefit

Market Focus
·
Yesterday

Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint

Reuters
·
Yesterday

HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off

Stock News
·
Yesterday

AKESO's Novel Dual Antibody Achieves Positive Phase III Results in Biliary Tract Cancer, Marking First Solid Tumor Expansion Beyond Lung Cancer

Stock News
·
Yesterday

Akeso: Ivonescimab Plus Chemotherapy Delivers Statistically Significant OS Improvement in Phase III Biliary Tract Cancer Trial

Bulletin Express
·
Yesterday

Akeso - Ivonescimab Plus Chemo Meets Primary Endpoint with Significant Os Benefit in 1L BTC

THOMSON REUTERS
·
Yesterday

Akeso - Harmoni-Gi1 First Phase Iii Study to Show Significant Os Benefit Versus Global Standard in Biliary Tract Cancer

THOMSON REUTERS
·
Yesterday

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: Harmoni-Gi1 Meets Primary Endpoint

THOMSON REUTERS
·
Yesterday

Akeso - Study Meets Key Secondary Endpoints of Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Yesterday

Movement Alert|AKESO Rises 3.49% in Regular Trading, Interim Results Imminent and New ADC Pipeline Progress Boosts Sentiment

Market Focus
·
Aug 24

Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors

Reuters
·
Aug 21

Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

THOMSON REUTERS
·
Aug 21

Movement Alert|AKESO Declines 3.41% in Regular Trading, Profit-Taking Resumes After Prior Sessions Sharp Rebound

Market Focus
·
Aug 21

Movement Alert|AKESO Rises 6.49% in Regular Trading, Earnings Preview and Technical Rebound After Overselling Drive Recovery

Market Focus
·
Aug 20

Akeso (SEHK:9926) Could Be 47% Undervalued As China Approves Ivonescimab Use

Simply Wall St.
·
Aug 19